Searched for
MOLNUPIRAVIR PRICE
Divi’s Labs Q3 preview: PAT may grow 33% YoY on favourable base; outlook eyedThe consolidated net profit for the quarter is seen rising 33% YoY to Rs 407.40 crore, according to the average of estimates given by five ...- Merck, Pfizer rebuff China's push for deeper price cuts on Covid drugsThe apparent rebuff coincides with a similar deadlock over Pfizer Inc's antiviral Paxlovid. Talks between the drugmaker and the Chinese age...
- Companies stare at huge losses as unsold Covid drugs pile upDuring the past two years, there were sky-rocketing sales of Covid-19 portfolio of drugs, sometimes even severe shortages. But now the indu...
- How does Merck's COVID-19 pill compare to Pfizer's?Merck in November said its full trial results showed that molnupiravir lowered the chance of hospitalization or death by about 30% in patie...
- Biophore India receives licences from MPP to market molnupiravirThe licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company ...
- Natco Pharma signs pact with MPP to sell Molnupiravir capsulesNatco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...
- India to become hub for Covid-19 antiviral generic drugs: FitchGeneric molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...
- Covid antiviral drug Molnupiravir has 'major safety concerns', says ICMRFlagging the various health concerns surrounding the Covid anti-viral drug Molnupiravir, ICMR’s Dr Balram Bhargava said that Merck’s corona...
- Dr Reddy's launches molnupiravir at Rs 35 per pill, matching Mankind's priceDr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...
- A full Molnupiravir treatment likely to cost up to Rs 3,000The recommended dose of molnupiravir is 800 mg twice a day for five days. With companies planning to launch 200 mg capsules, a patient will...
- Pharma stocks gain as DGCI approves emergency use of COVID pill MolnupiravirShares of Strides Pharma were up 2.3 per cent while those of Cipla gained 1.4 per cent. Dr Reddy’s scrip registered a gain of close to a pe...
- Natco Pharma plans to launch Molnupiravir capsules this week for treatment of COVID-19Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...
- Companies race to make COVID antiviral drug molnupiravir available in pharmaciesDrug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...
- Sun Pharma gets DCGI nod to market molnupiravir for COVID-19 treatmentEarlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...
- U.S. FDA authorizes Merck's at-home antiviral COVID-19 pillMerck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a cl...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- UK authorizes Merck's coronavirus pill, the first shown to be effective at treating COVID-19The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe...
- WHO-led programme aims to buy antiviral COVID-19 pills for $10 - documentThe ACT-A asks the G20 and other donors for additional funding of $22.8 billion until September 2022 which will be needed to buy and distri...
- MSD in talks with Medicines Patent Pool for additional licenses for molnupiravirMSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...
- Natco Seeks emergency approval to launch Molnupiravir for Covid-19 in IndiaMolnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...
Load More
